whether the FDA needs to further restrict or ban the use of Rezulin (troglitazone) for diabetes

Experts are questioning whether the FDA needs to further restrict or ban the use of Rezulin (troglitazone) for diabetes. ...

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote